Mr. Maloney has 32 years of Pharmaceutical Industry experience in both strategic and operational leadership. Since joining Novartis in 2003 he has held various positions of increasing responsibility in the United States, Switzerland, and Canada. After leading the US cardiovascular business, he moved to Switzerland to lead the $7-billion Global cardiovascular and metabolism business. In 2011, He successfully launched the company’s Primary Care Franchise, contributing to the success of treatments for diabetes, hypertension, heart failure, and respiratory diseases. In 2014, Mr. Maloney was appointed Country Head and President for Novartis Pharmaceuticals Canada. In this role he served as Chair of the Country Executive Committee. In addition, he served as a member of the Board of Directors of Innovative Medicines Canada (IMC) and Chair of the Atlantic Sub-Committee. Prior to joining Novartis, Mr. Maloney held sales, marketing, and leadership positions, with Pfizer and its predecessor companies, Upjohn and Pharmacia.
Mr. Maloney recently announced his plan for retirement in May 2018, and transitioned to the role of Strategic Advisor for Latin America and Canada until that time.